Evidence map›Paper›PMID 42786557›Full record

ArticleImmunoHorizons2026

SERPINB1 as a critical regulator of inflammation and protease activity in human monocytic cells.

Jareb J Pérez-Caraballo, Xiang Ye, Jian Cui, Rubén Martínez-Barricarte

Abstract read
In one paragraph

Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jareb J Pérez-CaraballoDivision of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Xiang YeDivision of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Jian CuiDivision of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Rubén Martínez-BarricarteDivision of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.ORCID 0000-0001-7925-449X

Funding

The role of SERPINB1 in T cell function and its contribution to human diseasesR01AI168210 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ruben Martinez Barricarte · 2023 to 2026
$2.6M
National Institute of Allergy and Infectious Diseases R01AI168210NIAID NIH HHS R01 AI168210
6 · The paper itself

Abstract

SERPINB1, a member of the serpin superfamily, functions primarily as a serine protease suicide inhibitor via its reactive center loop (RCL). While murine studies have elucidated its role in neutrophil homeostasis and survival, the functions and pathways orchestrated by human SERPINB1, particularly in monocytes, remain largely undefined. Here, we demonstrate that SERPINB1 is under purifying selection, indicative of an essential, non-redundant role in human immunity comparable to that of genes known to cause immune diseases when mutated. Flow cytometric and Western blot analyses reveal ubiquitous expression in immune cells, with monocytes exhibiting the highest levels and the most active utilization of SERPINB1. Using CRISPR/Cas9-mediated knockout in THP-1 monocytic cells, we found that SERPINB1 deficiency does not impair cell viability but significantly enhances proinflammatory responses, notably increasing IL-1β production in response to lipopolysaccharide stimulation. Bulk RNA sequencing corroborated upregulation of inflammatory genes, while activity-based proteomic profiling uncovered broad alterations in enzymatic activity, affecting pathways beyond protease regulation, including ribosomal function and cellular metabolism. These findings suggest that human SERPINB1 extends its function beyond protease inhibition to modulate monocyte inflammatory activation and metabolic processes. Further mechanistic investigations are warranted to delineate the molecular interactions underpinning SERPINB1's regulatory network in monocytes. Yet, our study provides novel insights into SERPINB1's multifaceted functions in human immunity and highlights its potential as a therapeutic target for controlling dysregulated inflammation.

Indexed as

InflammationMonocytesPeptide HydrolasesSerpinsHumansInterleukin-1betaLipopolysaccharidesProteomicsTHP-1 CellsInterleukin-1betaLipopolysaccharidesPeptide HydrolasesSERPINB1 protein, humanSerpinsmonocytesproteomicsserine protease inhibitorsSERPINB1THP-1

Identifiers

PMID42786557
PMCPMC13612166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.